Recce Pharmaceuticals Provides Business Update
SYDNEY, Australia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic...
News
Jushi Holdings Inc.’s BEYOND / HELLO to Open Its Second Retail Location in Sauget, Illinois, Its 13th Dispensary Nationally and Third in the State
Jushi Holdings Inc.’s BEYOND / HELLO to Open Its Second Retail Location in Sauget, Illinois, Its 13th Dispensary Nationally and...
Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty...
Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast
VANCOUVER, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging...
Jushi Holdings Inc. Provides Update on Acceleration of Warrants Expiry Date
Acceleration of warrants results in approximately USD$32 million in gross proceeds to the CompanyBOCA RATON, Fla., Dec. 21, 2020 (GLOBE...
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company...
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
Data to be Published in a Peer-Reviewed Journal in First Half 2021YAVNE, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- MediWound...
Profound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO®
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to...
The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
PLEGRIDY is now approved in the European Union for intramuscular injection, offering individuals with relapsing multiple sclerosis (MS) a differentiated,...
Golden Leaf Announces Non-Brokered Private Placement of Up To C$3,000,000
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR...
Cyclerion Announces Leadership Transitions
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating...
Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering,...
Microbix & Copan Italia Execute Strategic Agreement
For FLOQ devices & QAPs Co-branding, IP licensing, Co-marketing, Purchase and SupplyMISSISSAUGA, Ontario and BRESCIA, Italy, Dec. 21, 2020 (GLOBE...
Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new...
SI-BONE, Inc. Announces that Priority Health Became the 36th Payor with Exclusive iFuse Coverage Policy
Updated Blue Cross Blue Shield Association Evidence Rating Supports only Triangular ImplantsSANTA CLARA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) --...
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
First gene therapy to receive full EU marketing authorization for eligible MLD patients One-time treatment with Libmeldy has been shown to...
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a...
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building...